| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Head of Research & Development | Director
1 company
Robert Martell last filed a Form 4 in June 2025, as Head of Research & Development at CRIS. Robert Martell's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 23,027 shares of CRIS. The CRIS filings lean toward selling, a net 5,500 shares.
Robert Martell has 14 Form 4 filings on record from January 2015 to June 2025, across 2 companies: Director at Indaptus Therapeutics (INDP), 2023–2025; Head of Research & Development at Curis (CRIS), 2015–2023.
The 15 reported transactions were 12 option or other derivative awards, 1 tax withholding, 1 open-market sale and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $6K.
The only open-market sale was 5,500 shares of CRIS at an average $1.07 on January 23, 2019, about $6K.
Shares as reported in the last Form 4 for each company; the most recent is from June 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2019 | CRIS Curis Inc | Head of Research & Development | Sell | 5,500 | $1.07 | $5,900.40 | -19.3% |